前列腺癌患者雄激素剥夺治疗过程中的心血管疾病管理  

Management of cardiovascular health in prostate cancer patients with androgen deprivation therapy

作　　者：陈轶前 张维宇[1] 李晓丹[2] 徐涛[1] Chen Yiqian;Zhang Weiyu;Li Xiaodan;Xu Tao(Department of Urology,Peking University People’s Hospital,Beijing 100044,China;Department of Obstetrics and Gynecology,Peking University People’s Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院泌尿外科,北京100044 [2]北京大学人民医院妇产科,北京100044

出　　处：《中华泌尿外科杂志》2022年第11期873-876,共4页Chinese Journal of Urology

基　　金：国家自然科学基金(82071777);北京大学医学部交叉基金(BMU2020MX002)。

摘　　要：雄激素剥夺治疗是前列腺癌的主要治疗手段之一,但其造成的心血管事件已成为与肿瘤并列的致死原因。其机制可能与睾酮水平升高、促卵泡生长激素水平上升及动脉粥样硬化斑块不稳定有关。对该人群开展规范的心血管疾病管理,是提高生存和改善预后的关键问题。本文归纳总结涵盖病史收集与检查、评估、转诊、健康教育、方案选择这5个方面的管理方案。Androgen deprivation therapy is one of the main treatments for prostate cancer patients.In recent years,many studies have revealed that androgen deprivation therapy increases the risk of cardiovascular disease,which leads to the cause of death alongside tumor-related deaths.The mechanism may be related to the elevation of testosterone levels,follicle-stimulating hormone levels and unstable atherosclerotic plaque.Standardized cardiovascular disease management in this population is a key issue to improve survival and prognosis.This paper summarizes a management plan covering 5 areas,including history collecting and data examination,assessment,referral,health education,and regimen selection.

关 键 词：前列腺肿瘤 癌 雄激素剥夺治疗 心血管疾病 管理 

分 类 号：R737.25[医药卫生—肿瘤]